Generics 45

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Carbidopa manufacturers

45 products found

Filters

45 products found

carbidopa + levodopa

Tablets 12.5mg + 50 mg, 25mg + 100mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Australia , United States , Vietnam
Registered in
Finland , Germany , Italy , Netherlands , Spain , Sweden , United Kingdom
Available for
Licensing with supply, Distribution only, Technology transfer
MAs for sale
Austria , Estonia , Germany , Ireland , Italy , Latvia , Lithuania , Netherlands , Poland
Manufacturer #9438
A pharmaceutical manufacturer based in Europe that has been active in 10+ countries selling its products in Europe for 10+ years. Key production lines are Rx, OTC, dermo-cosmetics, and nutraceuticals. The main therapeutic areas include antibiotics.

Manufacturer usually replies in 6 days

carbidopa + levodopa

Tablets 25mg + 100mg, 25mg + 250mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Registered in
Czech Republic , Germany , Portugal
Manufacturer #9438
A pharmaceutical manufacturer based in Europe that has been active in 10+ countries selling its products in Europe for 10+ years. Key production lines are Rx, OTC, dermo-cosmetics, and nutraceuticals. The main therapeutic areas include antibiotics.

Manufacturer usually replies in 6 days

carbidopa + levodopa

Tablets 12.5 mg /50mg, 10 mg /100mg, 25 mg /100mg, 25 mg /250mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Registered in
Sweden , Ireland , Netherlands , United Kingdom
Manufacturer #9438
A pharmaceutical manufacturer based in Europe that has been active in 10+ countries selling its products in Europe for 10+ years. Key production lines are Rx, OTC, dermo-cosmetics, and nutraceuticals. The main therapeutic areas include antibiotics.

Manufacturer usually replies in 6 days

carbidopa + levodopa + entacapone

Tablets 12,5mg+50mg+200mg, 25mg+100mg+200mg, 37,5mg+150mg+200mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
Manufacturer #554

Manufacturer usually replies in 3 days

carbidopa + levodopa

Tablets, immediate release (IR) 12.5 mg + 50 mg, 10 mg + 100 mg, 25 mg + 100 mg, 25 mg + 250 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #15070

A pharmaceutical manufacturer based in the EU that is selling its products in EU, CIS, and Asia. Key production lines are Rx, OTC, medical devices, and nutraceuticals. The company's production lines are EU GMP-compliant.

Manufacturer usually replies in 8 days

carbidopa + levodopa

Tablets, extended release (ER) 25 mg + 100 mg, 50 mg + 200 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #15070

A pharmaceutical manufacturer based in the EU that is selling its products in EU, CIS, and Asia. Key production lines are Rx, OTC, medical devices, and nutraceuticals. The company's production lines are EU GMP-compliant.

Manufacturer usually replies in 8 days

carbidopa + levodopa

Tablets 10 mg + 100 mg, 12.5 mg + 50 mg, 25 mg + 100 mg, 25 mg + 250 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #3044

Manufacturer usually replies in nan days

carbidopa + levodopa + entacapone

Tablets 12.50 mg + 50 mg + 200 mg, 37.5 mg + 150 mg + 200 mg, 25 mg + 100 mg + 200 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Pakistan
GMP approvals
Sri Lanka, Afghanistan, Vietnam, Cambodia, Myanmar
Manufacturer #21102

Manufacturer usually replies in 5 days

carbidopa + levodopa

Tablets for oral solution 50 mg + 200 mg, 25 mg + 100 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19884

Manufacturer usually replies in 6 days

carbidopa + levodopa

Tablets, extended release (ER) 25 mg + 100 mg, 50 mg + 200 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
United Arab Emirates
GMP approvals
EU GMP
Manufacturer #31061

carbidopa + levodopa

Tablets, immediate release (IR) 12.5 mg + 50 mg, 10 mg + 100 mg, 25 mg + 100 mg, 25 mg + 250 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
United Arab Emirates
GMP approvals
EU GMP
MAs for sale
Australia , Canada , Czech Republic , Denmark , Germany , Malta , New Zealand , Poland , Spain , United Kingdom
Manufacturer #31061

carbidopa + levodopa + entacapone

Tablets 12.5 mg + 50 mg + 200 mg, 18.75 mg + 75 mg + 200 mg, 25 mg + 100 mg + 200 mg, 31.25 mg + 125 mg + 200 mg, 37.5 mg + 150 mg + 200 mg, 50 mg + 200 mg + 200 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
South Korea
GMP approvals
PICS
Manufacturer #18058
The company was established in the 1980s. The company has a foundation for cGMP production which is the standard for manufacturing and quality control of safe and quality pharmaceuticals. They will continue to grow and leap forward to be a leading company in the “future pharmaceutical market” by developing safe and quality pharmaceuticals and thorough quality control of the developed pharmaceuticals.

Manufacturer usually replies in 22 days

carbidopa + levodopa

Tablets 25/250 mg, 100/25 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Lebanon
GMP approvals
WHO
Manufacturer #16968
The company was formed in the 1960s. It is a regional Pharmaceutical Company operating in the MENA region and committed to improving human health and well-being. It is focused on the following therapeutic lines: Cardio-metabolic, Neurology, Urology, Pain & Inflammation, Gastroenterology & Infectiology.

Manufacturer usually replies in 17 days

carbidopa + levodopa

Tablets, modified release (MR) 50+200mg, 25+100mg

Dossier type
US CTD
Dossier status
Under development
Country of origin
European Union
Manufacturer #411

Manufacturer usually replies in nan days

levodopa + carbidopa + entacapone

Tablets 50 mg + 12.5 mg + 200 mg, 75 mg + 18.75 mg + 200 mg, 100 mg + 25 mg + 200 mg, 125 mg + 31.25 mg + 200 mg, 150 mg + 37.5 mg + 200 mg, 175 mg + 43.75 mg + 200 mg, 200 mg + 50 mg + 200 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
Switzerland
GMP approvals
EU GMP
Unavailable markets
Germany , United Kingdom , Vietnam
Available for
Distribution only
Comments
Ref. Stalevo
Manufacturer #269
A pharmaceutical manufacturer based in the EU that is active in 100+ countries selling its products in Europe, North America, Africa, the Middle East, and Asia for 40+ years. Main therapeutic areas include CNS, cardiovascular medication, and anti-infectives. The company's production lines are EU GMP-compliant. Key production lines are Rx and OTC. The company owns 20+ branches in Europe, Africa, and Asia.

Manufacturer usually replies in 5 days

levodopa + carbidopa

Tablets, film coated 100 mg + 25 mg, 250 mg + 25 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Bolivia , Chile , Colombia , Costa Rica , Dominican Republic , El Salvador , Guatemala , Honduras , Nicaragua , Panama , Paraguay , Peru , Ukraine , Uruguay , Venezuela
Comments
DCP ongoing, RMS MT
Manufacturer #422

A pharmaceutical manufacturer based in the EU that has been active in 100+ countries selling its products in Europe, North America, Africa, the Middle East, and Asia for 40+ years. Main therapeutic areas include CNS, cardiovascular medication, and anti-infectives. The company's production lines are EU GMP-compliant. Key production lines are Rx and OTC. The company owns 20+ branches in Europe, Africa, and Asia.

Manufacturer usually replies in 5 days

levodopa + carbidopa

Tablets, film coated 100 mg + 25 mg, 250 mg + 25 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Bolivia , Chile , Colombia , Costa Rica , Dominican Republic , El Salvador , Guatemala , Honduras , Nicaragua , Panama , Paraguay , Peru , Ukraine , Uruguay , Venezuela
Comments
DCP ongoing, RMS MT
Manufacturer #422

A pharmaceutical manufacturer based in the EU that has been active in 100+ countries selling its products in Europe, North America, Africa, the Middle East, and Asia for 40+ years. Main therapeutic areas include CNS, cardiovascular medication, and anti-infectives. The company's production lines are EU GMP-compliant. Key production lines are Rx and OTC. The company owns 20+ branches in Europe, Africa, and Asia.

Manufacturer usually replies in 5 days

levodopa + carbidopa

Tablets 250 mg + 25 mg, 100 mg + 25 mg, 100 mg + 10 mg, 50 mg + 12.5 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Comments
Dossier availability date: Q2 2024
Manufacturer #519

Manufacturer usually replies in 6 days

levodopa + carbidopa

Tablets, modified release (MR) 100/25, 200/50

Dossier type
CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #253

levodopa + carbidopa + entacapone

Tablets 50/12,5/200mg - 75/18,75/200mg - 100/25/200mg - 150/37,5/200mg - 175/43,75/200mg -200/50/200mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
EU GMP
Unavailable markets
Albania , Uzbekistan
Manufacturer #281
It is a leading European pharmaceutical firm that strives to create a powerful global brand with innovative goods and services, as well as bold and pioneering activities, by working passionately to heal the lives they touch. The business was founded in the 1900s. In the interest of public health and the national economy, the firm launched the project to promote public awareness about the unintentional use of medications.

Manufacturer usually replies in 8 days

Want to view all 45 products? Create your free account today!

Carbidopa

Carbidopa is a drug used in the treatment of Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant because allows a greater proportion of peripheral levodopa to cross the blood–brain barrier for central nervous system effect, thus paving way for the best possible absorption. Parkinson’s disease damages the neurons that produce dopamine, the motor symptoms of PD appear, including tremor, rigidity, impaired balance, and includes loss of spontaneous movement. These are motor symptoms of PD related to depletion of the neurotransmitter (chemical messenger) dopamine in the brain. Carbidopa prevents the conversion of L-DOPA to dopamine peripherally, thus reducing the side effects caused by dopamine on the periphery, and finally increasing the concentration of L-DOPA and dopamine in the brain.
Many combinations of Carbidopa/levodopa carry the brand names of Kinson, Sinemet, Pharmacopa and Atamet.
Amerigens Pharmaceuticals Ltd, first approved product by the FDA containing only carbidopa in 2014. Initially, The combination treatment of carbidopa/levodopa was originally developed by Watson Labs, However, the historical information by the FDA brings back to the approval of this combination therapy by Mayne Pharma in 1992.

Forms and dosage

The combination of levodopa/carbidopa is sold as a regular tablet, an orally disintegrating tablet, an extended-release, long-acting tablet, and an extended-release, long-acting capsule to take by mouth. It is also sold as a suspension to be given into your stomach through a PEG-J tube or sometimes through a naso-jejunal tube using a special infusion pump.
The regular and orally disintegrating tablets are given three or four times a day and extended-
release capsule is usually taken three to five times a day. The suspension is usually given as a morning dose by infusion over 10 to 30 minutes and then as a continuous dose given by infusion over 16 hours.

The cost of Carbidopa

In the USA, the consumers have to pay an average retail price of $44.23 and in the UK a supply of 100 tablets of 25mg strength cost 35 pounds. In India, the same supply costs less than dollar for a generic brand.

How does it work?

Carbidopa works by inhibiting aromatic-L-amino-acid decarboxylase, an enzyme important in the biosynthesis of L-tryptophan to serotonin and in the biosynthesis of L-DOPA to dopamine (DA). Increased dopamine availability increases the effectiveness of the remaining neurons thus providing alleviation from symptoms for a time. However, exogenously provided, L-DOPA gets metabolized peripherally before reaching the blood–brain barrier. But, Carbidopa decreases peripheral DDC conversion of L-DOPA before it crosses the blood–brain barrier. Carbidopa acts as a peripheral DDC inhibitor, it has no effect on brain DDC conversion of L-DOPA to dopamine. As result of these actions, a greater proportion of the exogenously provided levodopa/L-DOPA reaches the brain

Finding Carbidopa Manufacturers and Suppliers

 
For sourcing Carbidopa, manufacturers and sellers, log onto Pipelinepharma’s B2B online market place. It is a sophisticated B2B marketplace platform which is powered by our intuitive interface, which helps you narrow down and compare options for you to make the best decision.
 
Pipelinepharma’s B2B online market place has a host of manufacturers and suppliers, making it the ideal sourcing platform. You can choose from the wide list of manufacturers and suppliers suitable for your specific sourcing and pricing needs.